Company Overview - Genmab A/S is an international biotechnology company focused on improving the lives of individuals with cancer and other serious diseases through innovative antibody medicines [2] - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a presence in North America, Europe, and Asia Pacific [3] Product and Pipeline - Genmab has developed a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), and immune-modulating antibodies [2] - The company has eight approved antibody medicines and is advancing a strong late-stage clinical pipeline with the aim of delivering transformative medicines to patients [2] Upcoming Events - Genmab's CEO, Jan van de Winkel, will present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:45 PM PST [1]